Manidipino Aurovitas (Manidipine Dihydrochloride)

Manidipine, the active ingredient in Manidipino Aurovitas, is a calcium channel blocker presented as an oral tablet for systemic use. It is indicated for the management of hypertension in adult patients, helping to lower elevated blood pressure.\n\nGNH India supplies Manidipino Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets European Union standards for safety and efficacy.

Manidipine is a dihydropyridine calcium channel blocker used in the treatment of hypertension.\n\nEssential hypertension: lowers elevated systolic and diastolic pressure.\nPrimary hypertension: helps achieve target blood‑pressure goals.\nHypertensive patients with cardiovascular risk: contributes to overall risk reduction.

Manidipine may cause a range of adverse reactions, most of which are mild and reversible.\n\nCommon Side Effects:\n- Headache: mild to moderate intensity.\n- Flushing: transient warmth and redness of the skin.\n- Peripheral edema: swelling of ankles or lower legs.\n- Dizziness: sensation of light‑headedness, especially on standing.\n- Nausea: mild gastrointestinal discomfort.\n\nSerious or Rare Side Effects:\n- Severe hypotension: marked drop in blood pressure requiring medical attention.\n- Myocardial infarction: rare occurrence of heart attack.\n- Hepatic dysfunction: abnormal liver enzyme elevations.\n- Allergic reactions: rash, pruritus, or urticaria.\n- Angioedema: swelling of face, lips, or throat.\n- Cardiac conduction abnormalities: bradyarrhythmias or heart block.

Before initiating therapy, clinicians should consider several safety measures.\n\nMonitor blood pressure: ensure adequate control without excessive drop.\nAssess hepatic function: adjust use in patients with liver impairment.\nCaution in elderly: start at lower dose due to increased sensitivity.\nAvoid abrupt discontinuation: taper to prevent rebound hypertension.\nUse with caution in heart‑failure patients: monitor for fluid retention.\nStore at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Manidipine can interact with several drug classes, influencing its efficacy or safety profile.\n\nMajor Interactions (Avoid):\n- Concomitant antihypertensives: risk of additive hypotension.\n- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase plasma concentrations.\n- Grapefruit juice: may elevate drug levels.\n\nModerate Interactions (Monitor Closely):\n- Diuretics: enhanced diuretic effect and electrolyte shifts.\n- Beta‑blockers: additive blood‑pressure lowering effect.\n- NSAIDs: may attenuate antihypertensive response.